Business
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
– Two independent launches underway in less than nine months, with two more on track for 2026 – – Growing pipeline of wholly owned medicines in neurology and
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Two independent launches underway in less than nine months, with two more on track for 2026 –\n\n\n– Growing pipeline of wholly owned medicines in neurology and cardiometabolic disease and leading technology for next-generation medicines –\n\n\n– Clear path to sustained positive cash flow –\n\n\n– Ionis to webcast Innovation Day at 8:30 a.m. ET –\n\n\n CARLSBAD, Calif.--(BUSINESS WIRE)--\nIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company’s recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss the current treatment landscape and substantial unmet needs for severe hypertriglyceridemia (sHTG) in advance of the potential olezarsen launch.\n\n\n“In less than nine months, we achieved two independent launches, marking significant progress toward our goal of transforming human health by bringing RNA-targeted medicines to people with serious diseases,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our accelerating growth is driven by an industry-leading pipeline, with two more independent launches planned for 2026, four partner launches by the end of 2027 and continued advancement of our leading technology platform to deliver next-generation medicines. Innovation Day highlights how Ionis is creating substantial and enduring value for patients and shareholders through groundbreaking science and the ability to deliver medicines now and in the future.”\n\n\nEvent location, webcast and replay information\n\n\nThe event will take place from 8:30 a.m. to 12:30 p.m. Eastern Time and will be webcast. Please click here to register for the event. A webcast replay will be available for a limited time at the Investor Events section of Ionis’ website.\n\n\nIonis owned program highlights:\n\n\nBuilding a leading cardiometabolic disease portfolio\n\n\n\nIonis’ TRYNGOLZA® (olezarsen) launch in familial chylomicronemia syndrome (FCS) in the U.S. is off to a strong start, with robust patient uptake, favorable physician engagement and positive access dynamics. Additionally, TRYNGOLZA was recently approved in the EU, with Sobi leading the commercial launch.\n\n\n\nPositive topline data from the Pha...